Regenxbio (RGNX) Research & Development (2014 - 2025)

Regenxbio's Research & Development history runs 12 years deep, the most recent figure standing at $59.6 million for Q4 2025.

• On a quarterly basis, Research & Development rose 18.32% year-over-year to $59.6 million in Q4 2025; TTM through Dec 2025 was $228.3 million, a 9.48% increase from a year earlier, with the FY2025 full-year figure at $228.3 million, up 9.48% from the prior year.
• Research & Development rose to $59.6 million in Q4 2025 per RGNX's latest filing, from $56.1 million in the prior quarter.
• Across five years, Research & Development topped out at $63.3 million in Q3 2022 and bottomed at $39.7 million in Q1 2021.
• The 5-year median for Research & Development is $55.7 million (2022), against an average of $54.6 million.
• Across the five-year window, Research & Development surged 40.04% in 2022 and fell 18.4% in 2024, its largest moves.
• Year by year, Research & Development stood at $48.0 million in 2021, then surged by 30.28% to $62.5 million in 2022, then decreased by 10.92% to $55.7 million in 2023, then dropped by 9.52% to $50.4 million in 2024, then advanced by 18.32% to $59.6 million in 2025.
• Per Business Quant, the three latest RGNX Research & Development figures stand at $59.6 million (Q4 2025), $56.1 million (Q3 2025), and $59.5 million (Q2 2025).